Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 93
- Registration Number
- NCT00190853
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Manchester, United Kingdom
A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 640
- Registration Number
- NCT00191061
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Allis, Wisconsin, United States
Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 520
- Registration Number
- NCT00191035
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Nashville, Tennessee, United States
Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT00191542
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Vaxjo, Sweden
Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-08-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT00191880
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Toronto, Canada
A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 400
- Registration Number
- NCT00190931
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Missouri, United States
Switching to Duloxetine From Other Antidepressants
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT00191932
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Wythenshawe, United Kingdom
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 180
- Registration Number
- NCT00191997
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Zamora, Spain
Duloxetine in the Treatment of Melancholic Depression
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT00191685
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Quebec City, Quebec, Canada
Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions.
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 4000
- Registration Number
- NCT00190905
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Indianapolis, Indiana, United States